

Contains No CBI

Contains No CBI

1



PHILLIPS PETROLEUM COMPANY

BARTLESVILLE, OKLAHOMA 74004 918 661-6600

~~"Contains No CBI"~~

HEALTH, ENVIRONMENT AND SAFETY

A

August 24, 1992

Compliance Audit Program
CAP ID#: 8ECAP-0075

1992 SEP -2 PM 1:16
OTS CBIC

CERTIFIED MAIL - RETURN RECEIPT

8EH0-92-12570

88920010754

INIT

Document Processing Center (TS-790)
Office of Pollution Prevention and Toxics
Environmental Protection Agency
401 M Street, SW
Washington, D. C. 20460

Attn: Section 8(e) Coordinator
(CAP Agreement)

Gentlemen:

Phillips Petroleum Company is submitting the enclosed sixty (60) reports (two boxes, numbered 1 and 2) of toxicological studies pursuant to category II.B.2.b of the CAP Agreement 8ECAP-0075 Reports. Reports being submitted contain no confidential business information.

We are sending an additional five boxes (box numbers 3-7) of reports of studies that have, previously, been submitted to the FYI coordinator of the Office of Pollution Prevention and Toxics by the American Petroleum Institute (API). These are being provided solely for the Agency's convenience.

For questions concerning this correspondence, please contact Fred Marashi at 918-661-8153.

Very truly yours,

Barbara J. Price

Barbara J. Price
Vice President
Health, Environment & Safety

Enclosure (Seven Boxes)

FFM/dh:29

3/7/95



Phillips Petroleum Company

CAP Identification Number: 8ECAP-0075
Pursuant to Category: II.B.2.b

Contains No CBI

67 (2)

Title of Study: Acute Toxicity Tests API 79-6 Diesel Fuel (Marketplace Sample)

Name of Chemical: Diesel Fuel

CAS#: 68334-30-5

Summary: The test material, API #79-6, Diesel Fuel (Marketplace Sample), caused acute dermal corrosion at 4 ml/kg and 8 ml/kg and hepatic toxicity at 8 ml/kg.

Fiche # 2134

Contact:

Fred Marashi
Phillips Petroleum Company
13 D2 PB
Bartlesville, OK 74004
Phone: 918/661-8153
Fax: 918/661-5664

BIORESEARCH LABORATORIES
August 6, 1980


Project No. 100-1


Subacute Dermal Toxicity
API #79-b
Diesel Fuel (Marketplace Sample)


Conducted By:
Elars Bioresearch Laboratories, Inc.
225 Commerce Drive
Fort Collins, Colorado 80524


Dates of Study:
May 21, 1979 - March 31, 1980

Report To:
American Petroleum Institute
2101 L Street Northwest
Washington, D.C. 20037


Kris L. Hansen, B.S., M.S.
Toxicology Technician
Study Coordinator


L. Steven Beck, D.V.M., M.S.
Assistant Director of Toxicology
Study Director


William H. Halliwell, D.V.M., Ph.D.
Pathologist


Douglas I. Hepler, Ph.D.
Vice President, Toxicity
Evaluation Division

REVIEWED BY QUALITY ASSURANCE: 

BEST COPY AVAILABLE


Westpath Laboratories, Inc.
Project Number 1014
June 23, 1980

Elurs Bioresearch Laboratories
Project Number 1443-F
API 79-C

QUALITY ASSURANCE STATEMENT

A quality assurance inspection was made of 20% of the data in this report and included inspection of pathologist's dictation to individual animal histopathology forms and review of tabular summaries.


Linda K. Hatler, B.S.
Quality Assurance


Date

ELARS

BIORESEARCH LABORATORIES
August 6, 1980

Product No. 100-100

Subacute Dermal Toxicity
API #79-6
Diesel Fuel (Marketplace Sample)

OBJECTIVE:

The study described herein was conducted to evaluate the dermal toxicity of the test material when applied in repeated doses over a period of two weeks.

MATERIALS AND METHODS:

1. Test Material:

The test material, a liquid in a metal container identified as API #79-6, Diesel Fuel (Marketplace Sample), was received by Elars on May 18, 1979, August 6, 1979 and December 14, 1979. The concentration, purity, and stability were not provided by the sponsor. The test material was stored in Elars' test material storage room.

2. Animals:

The 4 ml/kg dosage group and control group consisted of eight adult New Zealand White rabbits, four males and four females, weighing between 2 and 4 kg. The 8 ml/kg dose group consisted of six adult rabbits, three males and three females. The rabbits were purchased from Pel-Freeze Rabbitry, Rogers, Arkansas, L.I.T. Rabbitry, Aptos, California, and Dutchland Rabbitry, Denver, Pennsylvania. They were identified individually by metal ear tags and corresponding cage tags. The rabbits were allowed to acclimate at Elars at least one week. Purina Rabbit Chow[®] and fresh water were provided ad libitum. Throughout acclimation and testing, the rabbits were housed individually in standard laboratory rabbit cages.

ELRS

BIORESEARCH LABORATORIES
Subacute Dermal Toxicity
API 179-aProject No. 1440-F
August 6, 19701. Method:

The rabbits were shaved free of hair with a number 40 Oster[®] clipper blade prior to application of test material, rather than 24 hours before, as stated in the protocol. The shaved area on each animal constituted about 30 percent of the total body surface area.

The daily dosages used for this compound were 4 ml/kg and 8 ml/kg body weight, and an untreated control group. The rabbits were exposed to the test material for five consecutive days followed by a two day rest period and then again for five consecutive days. The test material was applied to four-inch square gauze sponges backed by plastic wrap. The sponges and plastic wrap were taped to the shaved area of the animals' backs with porous adhesive tape. The entire trunk of each rabbit was wrapped with elastic tape to prevent slippage of the patches. The rabbits remained bandaged for 24 hours, at which time the patches were removed and a new dose of test material was applied. This procedure was followed each day of the five day dosing period. During the two day rest period the animals were not dosed.

Observations for mortality, local reactions, and behavioral abnormalities were made daily during the 14 day period. Initial and final body weights were recorded.

Any animals which succumbed during the study as well as those killed with T-61 at the termination of the study were subjected to necropsy, and all significant gross pathological alterations were recorded. In addition, the following tissues were submitted for histopathologic examination: skin from the test site, liver, kidney, spleen and urinary bladder.

BEST COPY AVAILABLE



BIORESEARCH LABORATORIES
Subacute Dermal Toxicity
API 479-6

3

Project No. 1441-7
August 6, 1959

14

At Elars Bioresearch Laboratories, the tissues collected were fixed in 10% neutral buffered formalin. Afterwards, the tissues were trimmed, embedded in paraffin, sectioned at 4 to 5 microns, affixed to glass slides, and stained with hematoxylin and eosin. Histopathologic examination of the submitted tissues was conducted at Westpath Laboratories by William H. Halliwell, D.V.M., Ph.D., Diplomate: ACVP.

RESULTS:

Individual animal weights and doses are given in Tables 1-3 for dosage levels 4 ml/kg, 8 ml/kg, and the control, respectively. The most significant daily observation recorded at both test levels was the progressive deterioration of the test site area. The skin at the test area became necrotic; it appeared thickened, cracked, and was bleeding. Later it became green and odiferous.

Animals in the 4 ml/kg and 8 ml/kg dose groups exhibited weight losses averaging -0.3 kg and -0.55 kg, respectively. No mortality occurred in the 4 ml/kg dose group. There was 67% mortality in the 8 ml/kg dose group. The control animals showed an average weight gain of 0.2 kg during the study. No mortality occurred in this group.

In the 4 ml/kg dose group, gross necropsy revealed skin lesions in all animals. Several rabbits had congested kidneys and mottled livers of a friable consistency. In the 8 ml/kg dose group, gross necropsy revealed evidence of anorexia. The two rabbits that died on day 4 had hemorrhagic mesenteric lymph nodes as well as abnormal kidneys and livers. Rabbit #949, found dead on day 5, had a pale, friable liver. Skin lesions were present on the three rabbits that survived until day 14. These rabbits also had pale, congested kidneys and mottled livers.

BEST COPY AVAILABLE

ELARS

BIOL RESEARCH LABORATORIES
Subacute Dermal Toxicity
API #79-6

Project No. 1443-F
August 7, 1980

The histopathologic observations on selected tissues from rabbits exposed daily to 4 ml/kg and 8 ml/kg of test material and from untreated control rabbits are presented in accompanying Tables 4-6. The test material produced acanthosis, acute inflammation, chronic inflammation, crusting, dermal congestion, dermal edema, multifocal epidermal microabscesses, hyperkeratosis, epidermal necrolysis and parakeratosis in both groups treated with the test material. The severity of these cutaneous lesions varied from very slight to severe at all test sites and in each dose level.

The multifocal necrosis noted in livers of two of six high dose (8 ml/kg) treated rabbits varied in degree of insult from moderate to severe.

CONCLUSIONS:

The test material, API #79-6, Diesel Fuel (Marketplace Sample), caused acute dermal corrosion and resulted in obvious treatment related signs in 4 ml/kg and 8 ml/kg treatment groups during the 14 day observation period and at necropsy in the species examined.

The histopathologic observations of animals exposed to two dosages of the test material (API #79-6) revealed evidence of dermal toxicity at both dosage levels and hepatic toxicity at the 8 ml/kg dosage level.

PERSONNEL:

Personnel responsible for the collection and interpretation of data generated in the course of this study were Kris L. Hansen, B.S., M.S., Toxicology Technician and Study Coordinator; L. Steven Beck, D.V.M., M.S., Assistant Director of Toxicology and Study Director; Vicki J. Mills, B.S., Irma Aibinana, John A. Liddell, and Denise E. Morita, B.S., Toxicology Technicians; Jeanette Walker, Laboratory Technician; Terry A. Hewett, B.S., Laboratory Assistant; Douglas I. Hepler, Ph.D., Director of Toxicology; and William H. Halliwell, D.V.M., Ph.D., Pathologist.

RAW DATA:

Raw data regarding this study are to be found in Elars' notebooks #239 and #1505 in file #1443-F.

BEST COPY AVAILABLE

BIORESEARCH LABORATORIES
Subacute Dermal Toxicity
API #79-6

Project No. 1443-F
August 5, 1980

Table 1
Individual Animal Weights and Dosages
Dose Level 4 ml/kg, 0% Mortality
September 24, 1979

Animal Number	Sex	Body Wt. Day 0 (kg)	Dose (ml)	Body Wt. Terminal	Weight Gain (kg)	Termination Day
655	M	2.6	10.4	2.3	-0.3	14
657	M	2.2	8.8	2.2	0.0	14
659	M	2.8	11.2	2.5	-0.3	14
661	M	3.0	12.0	2.6	-0.4	14
648	F	2.8	11.2	2.3	-0.5	14
654	F	2.8	11.2	2.6	-0.2	14
656	F	2.9	11.6	2.6	-0.3	14
668	F	2.8	11.2	2.4	-0.4	14

Table 2
Individual Animal Weights and Dosages
Dose Level 8 ml/kg, 67% Mortality
March 17, 1980

Animal Number	Sex	Body Wt. Day 0 (kg)	Dose (ml)	Body Wt. Terminal	Weight Gain (kg)	Termination Day
947	M	2.5	20.0	2.1	-0.4	14
949	M	3.3	26.4	2.9	-0.4	5
951	M	2.8	22.4	2.4	-0.4	14
934	F	3.4	27.2	2.7	-0.7	4
936	F	3.3	26.4	2.6	-0.7	4
938	F	3.1	24.8	2.4	-0.7	14*

* Found dead day 14.

BEST COPY AVAILABLE



BIORESEARCH LABORATORIES
Subacute Dermal Toxicity
API #79-b

6

Project No. 1445-F
August 6, 1980

Table 3
Individual Animal Weights and Dosages
Dose Level 0 ml/kg, 0% Mortality
May 21, 1979

Animal Number	Sex	Body Wt. Day 0 (kg)	Dose (ml)	Body Wt. Terminal	Weight Gain (kg)	Termination Day
421	M	2.4	0	2.5	0.1	14
423	M	2.3	0	2.7	0.4	14
425	M	2.4	0	2.5	0.1	14
427	M	2.5	0	2.7	0.2	14
422	F	2.7	0	2.9	0.2	14
424	F	2.7	0	3.0	0.3	14
426	F	2.7	0	2.9	0.2	14
428	F	2.4	0	2.5	0.1	14

BEST COPY AVAILABLE

Westpath Laboratories, Inc.
Project Number 1014

Glaxo Bioresearch Laboratories
Project Number 1003-F
API 79-5

Table 4

INDIVIDUAL HISTOLOGIC OBSERVATIONS

4 ml/kg/day

Accession Number (90-)	N586	N58	N588	N589	N590	N591	N592	N593
Animal Number	655	657	659	661	648	654	656	
Sex	M	M	M	M	F	F	F	
Reason Discontinued	FS	FS	FS	FS	FS	FS	FS	
Days on Test	14	14	14	14	14	14	14	
LIVER							NR	NR
Abscess, focal								
Congested								
Mineralization								
Necrosis, multifocal								
Pericholangitis	1	1	1	1	1	1		
Vacuolar Degeneration, centrilobular								
KIDNEY		NR	NR	NR	NR	NR	NR	NR
Congested								
Mineralization, focal								
Mononuclear Cell Infiltrate, focal	1							
Mononuclear Cell Infiltrate, diffuse								
Nephrosis, tubular								
SPLEEN	NR	NR	NR	NR	NR	NR	NR	NR
Congested								
Hyperplasia, reactive								
URINARY BLADDER	NR	NR	NR	NR	NR	NR	NR	NR
SKIN (Test Site)								
Acanthosis		3	3	3	2	3	3	
Acute Inflammation	2	3	2	2	2	2	2	3
Chronic Inflammation	2	3	2	2	2	2	2	2
Crusting	4	2	3	3	1	3	3	4
Deep Pyoderma								
Dermal Congestion	3	2	3		2	3	3	2
Dermal Edema	3	2	3		2	3	3	2
Epidermal Microabscesses, multifocal				3				
Hyperkeratosis	3	3	3	3	2		4	4
Liquefactive Degeneration								
Necrolysis, epidermal	1	2	2			2	2	4
Parakeratosis				2		2		
OTHER LESIONS								
LUNG	TNP	TNP	TNP	TNP	TNP	TNP	TNP	TNP
Atelectasis								
Hemorrhage, interalveolar								
STOMACH	TNP	TNP	TNP	TNP	TNP	TNP	TNP	TNP
Congestion, mucosal								
Lymphoid Hyperplasia, submucosal								
Necrosis, mucosal								

KEY: Acc = Accidental Death
DOT = Died on Test
FS = Final Sacrifice
MS = Moribund Sacrifice
SS = Scheduled Sacrifice
NDT = Tissue Present, No
Diagnosis Tendered

TNP = Tissue Not Present
NR = Tissue Present, Not
Remarkable
AUT = Autolysis
O-NR = Paired Organ, Unilateral
Absence, Tissue Present,
Not Remarkable
O- = Unilateral Lesion

Severity
1 = Very Slight
2 = Slight or Small
3 = Moderate
4 = Severe

BEST COPY AVAILABLE

Westpath Laboratories, Inc.
Project Number 1014

S

Table 5

INDIVIDUAL HISTOLOGIC OBSERVATIONS

S ml/kg/day

Elars Bioresearch Laboratories
Project Number 1443-F
API 79-6

Accession Number (80-)	834	835	836	837	838	839
Animal Number	934*	936*	938	947	949	951
Sex	F	F	F	M	M	M
Reason Discontinued	DOT	DOT	DOT	FS	DOT	FS
Days on Test	4	4	14	14	4	14
LIVER						
Abscess, focal						
Congested						
Mineralization						
Necrosis, multifocal			4		3	
Pericholangitis				1	2	1
Vacuolar Degeneration, centrilobular						
KIDNEY						
Congested			2			
Mineralization, focal						
Mononuclear Cell Infiltrate, focal					2	
Mononuclear Cell Infiltrate, diffuse						
Nephrosis, tubular						
SPLEEN						
Congested						
Hyperplasia, reactive						
URINARY BLADDER						
Degeneration, ballooning						
SKIN (Test Site)						
Acanthosis			2	2		3
Acute Inflammation			2	2	2	4
Chronic Inflammation			1	1	2	2
Crusting			1	2		3
Deep Pyoderma						
Dermal Congestion			2	2		2
Dermal Edema			2	2		2
Epidermal Microabscesses, multifocal						
Hyperkeratosis			3	3		3
Liquefactive Degeneration						
Necrolysis, epidermal					4	4
Parakeratosis						
ANY OTHER LESIONS						
HEART						
Hemorrhage						
Inflammation, acute			1			

KEY: Acc = Accidental Death
DOT = Died on Test
FS = Final Sacrifice
MS = Moribund Sacrifice
SS = Scheduled Sacrifice
NDT = Tissue Present, No
Diagnosis Tendered

TNP = Tissue Not Present
NR = Tissue Present, Not
Remarkable
AUT = Autolysis
O-NR = Paired Organ, Unilateral
Absence, Tissue Present,
Not Remarkable
O- = Unilateral Lesion

Severity

1 = Very Slight
2 = Slight or Small
3 = Moderate
4 = Sever-

No tissues taken

BEST COPY AVAILABLE

Outpath Laboratories, Inc.
Project No. 1014

Table 2

Elms Microbeam Laboratories
Project Number 1443-F
API 79-6

INDIVIDUAL HISTOLOGIC OBSERVATIONS

Control

Accession Number	N225	N226	N227	N228	N229	N230	N231	N232
Animal Number	421	422	423	424	425	426	427	428
Sex	M	F	M	F	M	F	M	F
Reason Discontinued	FS							
Days on Test	14	14	14	14	14	14	14	14
LIVER			NR		NR	NR		
Abscess, focal				4			4	
Congested								
Mineralization								
Necrosis, multifocal								
Pericholangitis	1	3						1
Vacuolar Degeneration, centrilobular	3							
KIDNEY	NR							
Congested								
Mineralization, focal								
Mononuclear Cell Infiltrate, focal								
Mononuclear Cell Infiltrate, diffuse								
Nephrosis, tubular								
SPLEEN			NR		NR	NR		NR
Congested							1	
Hyperplasia, reactive	2	1		2			2	
URINARY BLADDER	NR							
SKIN (Test Site)	NR							
Acanthosis								
Acute Inflammation								
Chronic Inflammation								
Crusting								
Deep Pyoderma								
Dermal Congestion								
Dermal Edema								
Epidermal Microabscesses, multifocal								
Hyperkeratosis								
Liquefactive Degeneration								
Necrosis, epidermal								
Parakeratosis								
OTHER LESIONS								
LUNG	TNP							
Atelectasis								
STOMACH	NR	NR	NR		NR	NR	NR	NR
Congestion, mucosal								
Lymphoid Hyperplasia submucosal				2				

KEY: Acc = Accidental Death
DOT = Died on Test
FS = Final Sacrifice
MS = Moribund Sacrifice
SS = Scheduled Sacrifice
NDT = Tissue Present, No
Diagnosis Tendered

TNP = Tissue Not Present
NR = Tissue Present, Not
Remarkable
AUT = Autolysis
O-NR = Paired Organ, Unilateral
Absence, Tissue Present,
Not Remarkable
O- = Unilateral Lesion

Severity
1 = Very Slight
2 = Slight or Mild
3 = Moderate
4 = Severe

ELAB BIORESEARCH LABORATORIES
Acute Toxicity Tests

Project No. 1443

Analysis of Feed

The guaranteed analyses of feed for Purina Guinea Pig Chow[®], Purina Formulab Chow[®], and Purina Rabbit Chow[®], as provided on the manufacturer's labels are listed below. No additional analyses of feed were made.

Guaranteed Analysis of Feed

Nutritional Content	-----Type of Purina [®] Chow-----		
	Purina Guinea Pig Chow [®] 5025 (%)	Purina Formulab Chow [®] 5008 (%)	Purina Rabbit Chow, Checkers [®] 5301 (%)
Crude protein, minimum	18.0	23.0	16.0
Crude fat, minimum	4.0	6.5	2.0
Crude fiber, maximum	16.0	4.0	18.0
Ash, maximum	9.0	8.0	9.0
Added minerals, maximum	3.5	2.5	3.0



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

Barbara J. Price
Vice President
Health, Environment & Safety
Phillips Petroleum Company
Bartlesville, Oklahoma 74004

OFFICE OF
PREVENTION, PESTICIDES AND
TOXIC SUBSTANCES

MAY 08 1995

EPA acknowledges the receipt of information submitted by your organization under Section 8(e) of the Toxic Substances Control Act (TSCA). For your reference, copies of the first page(s) of your submission(s) are enclosed and display the TSCA §8(e) Document Control Number (e.g., 8EHQ-00-0000) assigned by EPA to your submission(s). Please cite the assigned 8(e) number when submitting follow-up or supplemental information and refer to the reverse side of this page for "EPA Information Requests".


All TSCA 8(e) submissions are placed in the public files unless confidentiality is claimed according to the procedures outlined in Part X of EPA's TSCA §8(e) policy statement (43 FR 11110, March 16, 1978). Confidential submissions received pursuant to the TSCA §8(e) Compliance Audit Program (CAP) should already contain information supporting confidentiality claims. This information is required and should be submitted if not done so previously. To substantiate claims, submit responses to the questions in the enclosure "Support Information for Confidentiality Claims". This same enclosure is used to support confidentiality claims for non-CAP submissions.

Please address any further correspondence with the Agency related to this TSCA 8(e) submission to:

Document Processing Center (7407)
Attn: TSCA Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
Washington, D.C. 20460-0001

EPA looks forward to continued cooperation with your organization in its ongoing efforts to evaluate and manage potential risks posed by chemicals to health and the environment.

Sincerely,


Terry R. O'Bryan
Risk Analysis Branch

Enclosure

12570A



Recycled/Recyclable
Printed with Soy/Canola Ink on paper that
contains at least 50% recycled fiber

Triage of 8(e) Submissions

Date sent to triage: 12/14/95

NON-CAP

CAP

Submission number: 12570A

TSCA Inventory: Y N D

Study type (circle appropriate):

Group 1 - Dick Clements (1 copy total)

ECO AQUATO

Group 2 - Ernie Falke (1 copy total)

ATOX SBTOX SEN w/NEUR

Group 3 - Elizabeth Margosches (1 copy each)

STOX CTOX EPI RTOX GTOX
STOX/ONCO CTOX/ONCO IMMUNO CYTO NEUR

Other (FATE, EXPO, MET, etc.): _____

Notes:

THIS IS THE ORIGINAL 8(e) SUBMISSION; PLEASE REFILE AFTER TRIAGE DATABASE ENTRY

For Contractor Use Only	
entire document: <u>0</u> 1 2 pages <u>1</u>	pages <u>1, 2, tab</u>
Notes:	
Contractor reviewer : <u>LPS</u>	Date: <u>4/14/95</u>

CECATS/TRIAGE TRACKING DBASE ENTRY FORM

CECATS DATA: Submission # BEHQ-0992-12570 SEQ. A

TYPE: INT SUPP FLWP

SUBMITTER NAME: Phillips Petroleum Company

INFORMATION REQUESTED: FLWP DATE:
 0501 NO INFO REQUESTED
 0502 INFO REQUESTED (TECH)
 0503 INFO REQUESTED (VOL. ACTIONS)
 0504 INFO REQUESTED (REPORTING RATIONALE)
 DISPOSITION:
 0678 REFER TO CHEMICAL SCREENING
 0678 CAP NOTICE

VOLUNTARY ACTIONS:
 0401 NO ACTION REPORTED
 0402 STUDIES PLANNED/UNDIRWAY
 0403 NOTIFICATION OF WORKER CONCERNS
 0404 LABEL/MSDS CHANGES
 0405 PROCESS/HANDLING CHANGES
 0406 APP/USE DISCONTINUED
 0407 PRODUCTION DISCONTINUED
 0408 CONFIDENTIAL

SUB. DATE: 08/24/92 OTS DATE: 09/02/92 CSRAD DATE: 03/07/95

CHEMICAL NAME:

CAS#

68334-30-5

INFORMATION TYPE:	P F C	INFORMATION TYPE:	P F C	INFORMATION TYPE:	P F C
0201 ONCO (HUMAN)	01 02 04	0216 EPI/CLIN	01 02 04	0241 IMMUNO (ANIMAL)	01 02 04
0202 ONCO (ANIMAL)	01 02 04	0217 HUMAN EXPOS (PROD CONTAM)	01 02 04	0242 IMMUNO (HUMAN)	01 02 04
0203 CELL TRANS (IN VITRO)	01 02 04	0218 HUMAN EXPOS (ACCIDENTAL)	01 02 04	0243 CHEM/PHYS PROP	01 02 04
0204 MUTA (IN VITRO)	01 02 04	0219 HUMAN EXPOS (MONITORING)	01 02 04	0244 CLASTO (IN VITRO)	01 02 04
0205 MUTA (IN VIVO)	01 02 04	0220 ECO/AQUA TOX	01 02 04	0245 CLASTO (ANIMAL)	01 02 04
0206 REPRO/TERATO (HUMAN)	01 02 04	0221 ENV. OCCUREL/FATE	01 02 04	0246 CLASTO (HUMAN)	01 02 04
0207 REPRO/TERATO (ANIMAL)	01 02 04	0222 EMER INCI OF ENV CONTAM	01 02 04	0247 DNA DAM/REPAIR	01 02 04
0208 NEURO (HUMAN)	01 02 04	0223 RESPONSE REQUEST DELAY	01 02 04	0248 PROD/USE/PROC	01 02 04
0209 NEURO (ANIMAL)	01 02 04	0224 PROD/COMP/CHEM ID	01 02 04	0251 MSDS	01 02 04
0210 ACUTE TOX. (HUMAN)	01 02 04	0225 REPORTING RATIONALE	01 02 04	0299 OTHER	01 02 04
0211 CHR. TOX. (HUMAN)	01 02 04	0226 CONFIDENTIAL	01 02 04		
0212 ACUTE TOX. (ANIMAL)	01 02 04	0227 ALLERG (HUMAN)	01 02 04		
0213 SUB ACUTE TOX (ANIMAL)	01 02 04	0228 ALLERG (ANIMAL)	01 02 04		
0214 SUB CHRONIC TOX (ANIMAL)	01 02 04	0239 METAB/PHARMACO (ANIMAL)	01 02 04		
0215 CHRONIC TOX (ANIMAL)	01 02 04	0240 METAB/PHARMACO (HUMAN)	01 02 04		

TRIAGE DATA:

NON-CBI INVENTORY

ONGOING REVIEW

SPECIES

TOXICOLOGICAL CONCERN:

USE:

PRODUCTION:

YES

YES (DROP/REFER)

RGT

LOW

CAS SR

NO

NO (CONTINUE)

MED

IN PLANNING

REFER

HIGH

COMMENTS:

12570A

L

Subacute dermal toxicity in the rabbit is of low concern. New Zealand white rabbits received occluded applications of 0, 4,000 (4/sex), or 8,000 mg/kg (3/sex) of diesel fuel (conversion based on 4 or 8 mL/kg assuming a density of 1 for material) for five days, followed by a two-day rest period, then a second 5-day exposure. At the lower dose, no animals died; however, at 8,000 mg/kg, 4/6 animals died. At both doses, the exposed skin became necrotic, with thickening, cracked appearance and bleeding, followed by a green color and odor. At necropsy, abnormalities in the liver (mottling, pale color, friable consistency, and in 2/6 high dose animals, multifocal necrosis) and kidney (congestion, pale color) at both doses. Animals at the higher dose also had anorexia and hemorrhage of the mesenteric lymph nodes (2/6). Severe skin lesions (acanthosis, pyoderma, hyperkeratosis) were seen in all treated animals.